AURIGENE
5.7.2022 09:32:05 CEST | Business Wire | Press release
The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx's pioneering business model to accelerate the development of drug candidates in the areas of oncology and immune-inflammatory diseases and improve global access to innovative medicines.
Under the terms of the collaboration agreement, Aurigene and EQRx will collaborate on drug discovery, pre-clinical and clinical development and commercialization. Aurigene will lead drug discovery and pre-clinical development efforts, and EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialization efforts. The parties would share both funding for the discovery and development of the programs and financials resulting from the commercialization of any eventual drug candidates.
“This agreement with EQRx further validates Aurigene’s proven expertise in discovery and preclinical development of novel therapeutics and moves Aurigene forward into building a global oncology franchise participating in the end-to-end value chain,” said Murali Ramachandra, Ph.D., Chief Executive Officer of Aurigene. “We are excited to collaborate with EQRx and contribute to developing and delivering innovative medicines to patients at more affordable prices.”
“We are pleased to partner with Aurigene to expand our future pipeline and accelerate the discovery of next-generation therapeutics,” said Carlos Garcia-Echeverria, PhD, chief of Rx creation at EQRx. “Our combined efforts will focus on some of the most high-impact therapeutic targets across oncology and immune-inflammatory diseases. Given our mission, we believe these future programs hold the potential to create important treatments for patients and drive meaningful savings for healthcare systems around the world.”
About Aurigene
Aurigene Discovery Technologies Limited is a clinical stage biotech company committed to bringing novel therapeutics for the treatment of cancer and inflammation and a wholly owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY). Based in Bengaluru and Kuala Lumpur, Aurigene has developed deep expertise in cancer and inflammatory disorders, and has continuously invested in its people resources and infrastructure over the years. In the two decades of working with Pharma, Biotech and Academic partners, Aurigene has contributed to delivering 16 small molecule and peptide drug candidates, currently in clinical development. Aurigene has also out-licensed several first-in-class and best-in-class compounds to pharma and biotech companies for global clinical development, while undertaking clinical POC studies for a few programs on its own. For more information, please visit Aurigene’s website at www.aurigene.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005182/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons opens office in Madrid, betting on a promising pool of tech talent5.8.2026 09:00:00 CEST | Press release
Bending Spoons, the technology company behind products such as WeTransfer and Meetup, has opened an office in Madrid. The decision is underpinned by Spain’s strong talent pool, fuelled by excellent universities, and by Madrid’s international appeal and its quality of life. “We’re impressed by the talent we’ve seen in Spain. This year, we’ve received around 10,000 Spain-based applicants every month, and many of them perform among the very best candidates in our selection process. The calibre of education offered by Spanish universities is particularly high, and over the next few years we’re hoping to grow our team in Madrid into the hundreds,” says Andrea Maiorana, talent data lead. Located in the Recoletos area, the office is the company’s third European base, following the Milan headquarters and the recently opened London branch. The office is in one of the city's most coveted locations, within walking distance of Retiro Park and the Prado Museum. For new hires relocating to Madrid, B
Moove Raises $250 Million at $2.1 Billion Valuation to Scale the Global Infrastructure Layer for Autonomous Mobility5.8.2026 09:00:00 CEST | Press release
Led by Mubadala Investment Company "Mubadala", and co-led by Woven Capital (Toyota) and Ion Pacific, the Series C accelerates Moove’s global infrastructure platform for autonomous mobility as the market shifts from breakthrough technology to scaled deployment.$250 million Series C values Moove at $2.1 billion, cementing its position as the category defining infrastructure company for the autonomous mobility economyMoove is building the core operating layer for autonomous mobility globally through integrated fleet management, robotics-first depot infrastructure, and 24/7 operationsThrough its partnership with Waymo, Moove is already a leading third-party autonomous vehicle fleet manager, with operations live or announced across Phoenix, Miami and LondonMoove’s autonomous strategy is grounded in five years of building and operating mobility infrastructure at scale, from an initial launch of 76 vehicles in Lagos to approximately 42,000 vehicles across 29 cities (13 countries) and achievin
Network X Awards 2026 Finalists Announced, Spotlighting Telecom Innovation and Industry Excellence5.8.2026 08:00:00 CEST | Press release
Defining innovators recognised across AI, fibre, mobile networks, Wi-Fi and data centre infrastructure in Vienna Network X, the global event series bringing together the international fixed-line, transport and mobile telecom communities, today announced finalists for the fifth annual 2026 Network X Awards, recognising the companies, technologies and projects driving innovation across the global telecommunications industry. Celebrating excellence across 21 solution provider and operator categories, winners will be announced on 14 October during an awards ceremony at the Museum of Applied Arts (MAK) in Vienna. “The Network X Awards recognise the technologies, solutions and industry leaders actively shaping the next generation of global connectivity,” said Chris Lycett, Event Director, Network X. “With more companies entering than ever before, this year was the most competitive process to date. The finalists reflect an industry undergoing rapid transformation, from AI-driven network opera
European AI Startups Grab Record 55% of VC Capital as H1 Funding Reaches $23B5.8.2026 00:01:00 CEST | Press release
New HumanX/Crunchbase data shows a 130% YoY surge, though 73% of capital concentrated in just 38 breakout deals European AI startups raised a record-breaking $23 billion in the first half of 2026, a 130% year-over-year surge that captured 55% of all venture capital in the region, according to the 2026 European AI Economy Report released today by HumanX and Crunchbase. Up from $10 billion in H1 2025, the historic funding total signals that Europe is rapidly asserting itself as a primary engine of global AI innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804090835/en/ "If the AI story was supposed to be a two-horse race, Europe didn't get the memo," said Stefan Weitz, Co-Founder and CEO of HumanX. "$23 billion is flowing straight into the industries Europe already leads: robotics, healthcare, advanced manufacturing, defense. This is a continent betting on its own strengths." Capital concentrates in a small cohort
IFF Reports Second Quarter 2026 Results; Announces Use of Proceeds Plan for Food Ingredients Divestiture4.8.2026 22:15:00 CEST | Press release
Delivered Strong Sales, Profit and Cash Flow Performance in Second Quarter 2026Provides Full Year 2026 Financial Guidance on a Continuing Operations BasisAnnounces Enhanced $2.5B Share Repurchase Authorization; Including $500M Accelerated Share Repurchase in the second half of 2026 IFF (NYSE: IFF) reported financial results for the second quarter ended June 30, 2026. Results are presented on a continuing operations basis, excluding the Food Ingredients business and other minor perimeter adjustments (the “Food Ingredients disposal group”), and the Soy Crush, Concentrates, and Lecithin businesses (the “SCL disposal group”). The Food Ingredients disposal group and the SCL disposal group are reported as discontinued operations. Management Commentary “IFF delivered a strong first half of 2026 on a continuing operations basis,” said Erik Fyrwald, CEO of IFF. “Performance was driven by volume growth, disciplined margin execution and robust free cash flow generation. These results reflect the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom